DNB Asset Management AS Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

DNB Asset Management AS grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 26,015 shares of the biopharmaceutical company’s stock after purchasing an additional 1,022 shares during the quarter. DNB Asset Management AS’s holdings in Alnylam Pharmaceuticals were worth $6,322,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $30,000. GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $52,000. V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $52,000. Finally, Lindbrook Capital LLC boosted its stake in Alnylam Pharmaceuticals by 37.2% in the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,598 shares of company stock valued at $19,377,944. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.9 %

Shares of Alnylam Pharmaceuticals stock traded down $2.44 during mid-day trading on Tuesday, reaching $262.56. 1,349,532 shares of the stock traded hands, compared to its average volume of 899,166. The stock has a market capitalization of $33.21 billion, a PE ratio of -98.19 and a beta of 0.37. The business has a 50-day moving average of $211.34 and a 200 day moving average of $175.01. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $274.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. During the same quarter in the previous year, the business posted ($2.21) EPS. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays raised their target price on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday. Bank of America raised their price objective on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, UBS Group lifted their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $269.32.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.